Publications

Publications:

  1. Wang Y, Guo Z, Shu Y, Zhou H, Wang H, Zhang W. BART miRNAs: an unimaginable force in the development of nasopharyngeal carcinoma. Eur J Cancer Prev. 2016 Feb 23. [Epub ahead of print] PMID: 26909566
  2. Li Q, Yang H, Guo D, Zhang T, Polli JE, Zhou H, Shu Y. Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. Drug Metab Dispos. 2016 Apr;44(4):489-94. doi: 10.1124/dmd.115.067223. Epub 2016 Jan 29. PMID: 26825640
  3. Guo Z, Shu Y, Zhou H, Zhang W. Identification of diagnostic and prognostic biomarkers for cancer: Focusing on genetic variations in microRNA regulatory pathways. Mol Med Rep. 2016 Mar;13(3):1943-52. doi: 10.3892/mmr.2016.4782. Epub 2016 Jan 14. PMID: 26782081
  4. Wen J, Zeng M, Shu Y, Guo D, Sun Y, Guo Z, Wang Y, Liu Z, Zhou H, Zhang W. Aging increases the susceptibility of cisplatin-induced nephrotoxicity. Age (Dordr). 2015 Dec;37(6):112. doi: 10.1007/s11357-015-9844-3. Epub 2015 Nov 3. PMID: 26534724
  5. Wen J, Shu Y, Zhang W. ROS, P53, and ischemic acute kidney injury in diabetic models. Kidney Int. 2015 Jul; 88(1):198-9. doi: 10.1038/ki.2015.130.
  6. Guo Z, Shu Y, Zhou H, Zhang W, Wang H. Radiogenomics helps to achieve personalized therapy by evaluating patient responses to radiation treatment. 2015 Mar;36(3):307-17.
  7. Dong Z, Li Q, Guo D, Shu Y, Polli JE. Synthesis and Evaluation of Bile acid-ribavirin Conjugates as Prodrugs to Target the Liver. J Pharm Sci 2015 Feb 2. doi: 10.1002/jps.24375. [Epub ahead of print].
  8. Li L, Li H, Garzel B, Sueyoshi T, Li Q, Shu Y, Heyward S, Moeller T, Negishi M, Wang H. SLC13A5 is a novel transcriptional target of the pregnane X receptor and constitutive androstane receptor, and sensitizes drug-induced steatosis in human liver. Mol Pharmacol Apr; 87(4):674-82. doi: 10.1124/mol.114.097287. Epub 2015 Jan 27.
  9. Yang H, Shu Y. Cadmium Transporters in the Kidney and Cadmium-Induced Nephrotoxicity. J. Mol. Sci. 2015, 16, 1484-1494; doi:10.3390/ijms16011484
  10. Chen L, Shu Y, Li S, Xu L, Zur A, Keshari KR, Liang X, Chen E, Morrissey K, Rosenbaum A, Lin M, Liu J, Ostrem J, Yee SW, Younger N, Dal Porto J, Kurhanewicz J, Shokat KM, Ashrafi K, Giacomini KM. OCT1 is a high capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A. 2014 Jul 8; 111(27): 9983-8.
  11. Li Q, Shu Y. Role of Solute Carriers in Response to Anticancer Drugs. Molecular and Cellular Therapies 2014, 2:15.
  12. Liu MZ, McLeod HL, He FZ, Chen XP, Zhou HH, Shu Y*, Zhang W*. Epigenetic perspectives on cancer chemotherapy response. Pharmacogenomics. 2014 Apr;15(5):699-715
  13. Li Q, Guo G, Dong Z, Zhang W, Zhang LK, Huang S-M, Polli JE, Shu Y. Ondansetron Enhances Cisplatin-Induced Nephrotoxicity via Inhibition on Multiple Toxin and Extrusion Proteins (MATEs). Toxi Appl Pharmacol 2013 Aug 31. doi:pii: S0041-008X(13)00374-8. 10.1016/j.taap.2013.08.024. [Epub ahead of print]
  14. Chen WQ, Shu Y, Li Q, Xu LY, Roederer MW, Fan L, Wu LX, He FZ, Luo JQ, Tan ZR, He YJ, Zhou HH, Chen X, Zhang W. Polymorphism of ORM1 Is Associated with the Pharmacokinetics of Telmisartan. PLoS One 2013 Aug 5;8(8):e70341. doi: 10.1371/journal.pone.0070341. Print 2013.PMID: 23940561
  15. Li Q, Shu Y. Pharmacological Modulation of Cytotoxicity and Cellular Uptake of Anti-cancer Drugs by PDE5 Inhibitors in Cancer Cells. Pharm Res 2013 Jul 25. [Epub ahead of print] PMID: 23884568
  16. Li Q, Yang H, Peng X, Guo D, Dong Z, Polli JE, Shu Y. Ischemia/Reperfusion-Inducible Protein Modulates the Function of Organic Cation Transporter 1 and Multidrug and Toxin Extrusion 1. Mol Pharm 2013 Jun 3. [Epub ahead of print] PMID: 23651427
  17. Yang H., Li Q., Lee J.H. & Shu Y. Reduction in Tcf7l2 expression decreases diabetic susceptibility in mice. Int J Biol Sci. 2012; 8(6):791-801. PMID: 22719219.
  18. Li Q, Peng X, Yang H, Rodriguez JA, and Shu Y. Contribution of organic cation transporter 3 to cisplatin cytotoxicity in human cervical cancer cells. J Pharm Sci 2011 Sep 8. doi: 10.1002/jps.22752. [Epub ahead of print]
  19. Li Q, Peng X, Yang H, Wang H, and Shu Y. Deficiency of multidrug and toxin extrusion 1 enhances renal accumulation of paraquat and deteriorates kidney injury in mice. Mol Pharm. 2011 Dec 5;8(6):2476-83. Epub 2011 Oct 12.
  20. Diao L, Shu Y, Polli JE. Uptake of Pramipexole by Human Organic Cation Transporters. Mol Pharm. 2010 Jun 3. [Epub ahead of print]
  21. Shu Y. Research progress in the organic cation transporters.Journal of Central South University (Medical sciences). 2011 Oct; 36(10):913-26. PMID:22086000
  22. Black KL, Yin D, Ong JM, Hu J, Konda B, Wang X, Ko MK, Bayan J, Sacapano MR, Espinoza A, Irvin D, Shu Y. Phosphodiesterase 5 inhibitors enhance tumor permeability and efficacy of chemotherapy in rat brain tumor model. Brain Research 2008 Sep 16;1230:290-302. Epub 2008 Jul 14.
  23. Black KL, Yin D, Konda BM, Wang X, Hu J, Ko MK, Bayan J, Sacapano MR, Espinoza AJ, Ong JM, Irvin D, Shu Y. Increased brain tumor permeability in glioma-bearing rats with nitric oxide donors. Brain Research 2008 Aug 28;1227:198-206. Epub 2008 Jun 21.
  24. Yin D, Konda BM, Wang X, Hu J, Ko MK, Bayan J, Sacapano MR, Espinoza AJ, Ong JM, Irvin D, Shu Y, Black KL. Differences in brain tumor permeability between syngeneic and allogeneic rat brain tumor models related to KCa and KATP channel expression. Clinical Cancer Research 2008 Jun 15;14(12):4002-9.
  25. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. Journal of Clinical Investigation 2007 117:1422-31.
  26. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM, Giacomini KM. Effects of genetic variation in human organic cation transporter 1, hOCT1, on metformin pharmacokinetics. Clinical Pharmacology & Therapeutics, 2007 Jul 4; [Epub ahead of print]
  27. Shu Y, et al. PharmGKB submission update: V. PMT submissions of genetic variation in SLC22 family transporters. Pharmacological Reviews 2006; 58:3-4.
  28. Zhang S, Lovejoy K, Shima J, Lagpacan L, Shu Y, Lapuk A, Gray JW, Chen X, Lippard SJ, and Giacomini KM. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Research 2006 66: 8847-57.
  29. Shu Y, et al. PharmGKB update: III. Genetic variants of SLC22A1, solute carrier family 22 (organic cation transporter), member 1. Pharmacological Reviews 2004; 56: 161.
  30. Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D, Kawamoto M, Jeans SJ, DeYoung J, Carlson E, Ferrin TE, Herskowitz I, and Giacomini KM. Evolutionary conservation predicts function of genetic variants in the human organic cation transporter, OCT1. Proceedings of the National Academy of Sciences of the United States of America 2003; 100: 5902-7.
  31. Feng B, Shu Y, Giacomini KM. Role of aromatic transmembrane residues of the organic anion transporter, rOAT3, in substrate recognition. Biochemistry 2002; 41: 8941-7.
  32. Shu Y, Bello CL, Mangravite LM, Feng B, Giacomini KM. Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in MDCK cells. Journal of Pharmacology and Experimental Therapeutics 2001; 299: 392-398.
  33. Feng B, Dresser MJ, Shu Y, Johns SJ, Giacomini KM. Arginine 454 and Lysine 370 Are Essential for the Anion Specificity of the Organic Anion Transporter, rOAT3. Biochemistry 2001; 40: 5511-20.
  34. Jiang ZP, Shu Y, Chen XP, Huang SL, Zhu RH, Wang W, He N, Zhou HH. The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. European Journal of Clinical Pharmacology 2002; 58:109-13.
  35. Han XM, Ouyang DS, Chen XP, Shu Y, Jiang CH, Tan ZR, Zhou HH. Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. British Journal of Clinical Pharmacology 2002; 54: 540-3.
  36. Liu ZQ, Zhu B, Tan YF, Tan ZR, Wang LS, Huang SL, Shu Y, Zhou HH. O-dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 2002; 300:105-11.
  37. Shu Y, Chen ZN, Liu ZQ, Wang LS, Zhu B, Huang SL, Zhou HH. Interindividual variations in the levels and activities of cytochrome P-450s in liver microsomes of Chinese subjects. Acta pharmacologica Sinica 2001; 22: 283-288.
  38. Cheng ZN, Shu Y, Liu ZQ, Wang LS, Ou-Yang DS, Zhou HH. In vitro study the role of cytochrome P450s in estradiol metabolism. Acta pharmacologica Sinica 2001; 22: 148-154.
  39. Liu ZQ, Shu Y, Huang SL, Wang LS, He N, Zhou HH. Effect of the CYP2C19 genotype and 2C9 on fluoxetine N-demethylation in human liver microsomes. Acta Pharmacologica Sinica 2001; 22: 85-90.
  40. Wang JH, Liu ZQ, Wang W, Cheng XP, Shu Y, He N, Zhou HH. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clinical Pharmacology & Therapeutics 2001; 70: 42-7.
  41. Han XM, Ouyang DS, Lu PX, Jiang CH, Shu Y, Chen XP, Tan ZR, Zhou HH. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics 2001; 11: 429-35.
  42. Shu Y, Wang LS, Xu ZH, He N, Xiao WM, Wang W, Huang SL, Zhou HH. 5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity. Journal of Pharmacology and Experimental Therapeutics 2000; 295: 844-851.
  43. Shu Y, Wang LS, Xiao WM, Wang W, Hang SL, Zhou HH. Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole and omeprazole sulphone. Acta pharmacologica Sinica 2000; 21: 753-758.
  44. Shu Y, Zhou HH. Individual and ethnic differences in CYP2C19 activity in Chinese populations. Acta Pharmacologica Sinica 2000; 21: 193-199.
  45. Lu AH, Shu Y, Huang SL, Wang W, Ou-Yang DS, Zhou HH. In vitro proguanil activation to cycloguanil is mediated by CYP2C19 and CYP3A4 in adult Chinese liver microsomes. Acta Pharmacologica Sinica 2000; 21: 747-752.
  46. Ou-Yang DS, Huang SL, Wang W, Xie HG, Xu ZH, Shu Y, Zhou HH. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. British Journal of Clinical Pharmacology 2000; 49: 145-51.
  47. Shu Y, Zhou HH. Advances in cytochrome P450 pharmacogenetics. Trends in Pharmacology 2000; 3: 19-36. (Special review invited by Acta Pharmacologica Sinica)
  48. Xu ZH, Wang W, Zhao XJ, Huang SL, Zhu B, He N, Shu Y, Liu ZQ, Zhou HH. Evidence for involvement of polymorphic CYP2C19 and CYP2C9 in the N-desmethylation of sertraline by human liver microsomes. British Journal of Clinical Pharmacology 1999; 48: 416-423.
  49. Shu Y, Zhu RH, Xu ZH, Zhou HH. Determination of human liver microsomal amtriptyline and nortriptyline by reversed-phase high performance liquid chromatography. Acta pharmacologica Sinica 1998; 19: 343-346.
  50. Shu Y, Xu ZH, Xie HG, Zhu RH, Zhao JP, Zhou HH. Enzyme kinetic analysis and inhibition study of amitriptyline N-demethylation in human liver microsomes in vitro. Chinese Journal of Pharmacology and Toxicology 1998; 12: 260-265.
  51. Xie HG, Xu ZH, Ou-Yang DS, Shu Y, Yang DL, Wang JS, Yan XD, Huang SL, Wang W, Zhou HH. Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations. Pharmacogenetics 1997; 7: 503-514.